The weight-loss drug Wegovy is now available to patients in Canada.
Wegovy contains the same medication as Ozempic, which was specifically developed to treat type 2 diabetes.
The two drugs have the same active ingredient but Wegovy carries a higher weekly dose of semaglutide of 2.4 milligrams, compared to 1 mg in a single Ozempic dose.
Clinical trials showed that Wegovy was not only safe and effective for weight loss, but also had a positive impact on other weight-related measures such as blood pressure, blood sugar, and cholesterol levels.
The GLP-1 drugs slow digestion by keeping food in your stomach longer and sending signals to your brain to tell you you’re full, and research shows that it may even change your appetite for certain foods, like those high in calories.
In addition to patients with obesity, doctors can prescribe Wegovy to patients with a BMI of 27Kg/m2 and at least one weight-related medical condition. That could include hypertension, Type 2 diabetes, dyslipidemia, and obstructive sleep apnea.
For example: a man standing 5 foot 11 inches and weighing 200 lbs would have a BMI of 27.9Kg/m2. He would qualify if he had one weight-related medical condition.
In Canada, Wegovy is approved to be used with a reduced-calorie diet and increased physical activity.
The obesity drugs should be coupled with lifestyle changes to get the best results and minimize the chance of weight regain in the future.
One thing that isn’t clearly understood, however, is how these medications might affect adults ages 65 and up who are using them long-term.
For these reasons, seniors may require extra monitoring from their healthcare providers to mitigate potential health risks.
You should not rely on information tools for medical, financial or legal advice. It provides general information only. NICE is not responsible for any use of the information other than for general educational/informational purposes and no claim can be made against NICE or any of its personnel for any such use.
This is a collaborative effort, we welcome suggestions for new resources, videos, news, links to surveys and announcements.